Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
about
Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer CellsConvergence of Innate and Adaptive Immunity during Human AgingMultivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanomaArming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsThe therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptideEfficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy.Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT CellsImmune phenotypes predict survival in patients with glioblastoma multiforme.Cytokine-induced killer (CIK) cells: from basic research to clinical translation.IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus.Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.Effects of CIK on hypoxia inducible factor-1α and T-cell subsets on colon 26 cancer xenograft mice.Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model.Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells.Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors.Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells.Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma.An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma.Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis.Cancer Immunotherapy with Cytokine-Induced Killer Cells.Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.Increased numbers and functional activity of CD56⁺ T cells in healthy cytomegalovirus positive subjects.Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.Immune-Mediated Therapies for Liver Cancer.Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.
P2860
Q26751018-F2635A96-14EF-49D6-8798-729716B8214DQ28069527-24937036-69D4-4D83-82CB-65B3551FC0EDQ30664844-3A35D9FD-A058-4EDF-BF7B-7FE7F00FC6C7Q33884816-6DC6017F-31AE-450B-820A-6E4B90218A9EQ34350259-CACFEE20-442A-402E-AF91-556342226072Q34367252-B2C37ECE-DBB1-4BFC-BBC7-7E98DD6CC25DQ34419059-6568FABD-3456-45D7-9355-E3A7342DA237Q34446934-7C27E240-90E0-4E65-B5C9-CD4EF7ED8FD0Q35543911-645A53EF-6531-48C5-AC28-295C457C1217Q35755295-B33C524B-EFCF-4849-BC92-0D4390D4D3CDQ35870886-1A4A0D30-AA02-4982-8C2A-984CB4BA2B6AQ35959395-355BF142-CF2E-44C8-87C8-4A8A2F53D448Q36120388-7D60BC4D-FD76-49EB-AA4D-24C21BF3CB6CQ36121153-9AC4C7F2-2D74-471F-BB09-CD33C3FBEDCEQ36162835-B417F53D-8CD4-4AAF-8DBC-E788E10A423BQ36351988-F2BF1A0C-42F3-475D-9926-D91315E7E2E4Q36524871-C22D3BD6-A617-44C1-9425-2E67CEC942A6Q36592772-28B67DB3-2F99-4560-A8AE-01F662E98AE0Q37224604-70A05D93-FF27-49A6-B64E-0D56BDC11F5AQ37353913-928EFFE9-D3C5-4244-9C2B-D43696878F7EQ37704879-20EC9689-A2F0-4595-965B-55A69A449128Q37720231-26764E3A-3BAD-4F97-A0C4-0B183D6E0187Q38002494-DB0A2A08-2081-4987-B677-91D8124C5430Q38063500-5BFCFC1D-9D04-4DA3-8C39-365395FF2BAEQ38199717-B4B0969D-850F-4D6B-AC0B-0E4D0E47EEF9Q38201328-7D791EFE-8B04-4C06-AD31-34B76AA396C4Q38574526-534863AE-7A5A-4ACC-AF76-52A6D91B56B5Q38662119-3DA0862A-39D0-4273-AA25-F56C6060C30CQ38687547-665CBCC1-DA2A-4754-832F-1D817A4A1389Q38740111-F7E37E87-CF4C-42D8-959E-B90E1C2CDEEFQ38773798-5A24171A-86E6-483F-91CB-4F3264A448FAQ38787535-DB352012-00E0-46A2-A490-7A4A1B18E39AQ39026376-0F50238D-FC29-45D0-B98C-C7287F13C50EQ39033893-4108BC74-648A-4F6C-B681-B96B48A79680Q39049730-E869A413-3C80-4F74-8594-D927543629CBQ39144327-7784BC48-DCED-4316-A3A2-811BB5D00273Q39466599-3821ED83-E9E9-4BFD-8DAC-0C6B9865E1B2Q39667028-BA780597-B84F-42C1-96D9-16AC4097C084Q41595215-F4D908EF-502E-400B-91CD-048F49CACBA7Q41973053-8BCFDD96-487E-4B43-A2FB-FDD96A8FF572
P2860
Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@en
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@nl
type
label
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@en
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@nl
prefLabel
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@en
Cytokine-induced killer cells ...... cytotoxic T-EMRA lymphocytes.
@nl
P2093
P50
P1476
Cytokine-induced killer cells ...... 8 cytotoxic T-EMRA lymphocytes
@en
P2093
Alice Pievani
Gianmaria Borleri
Katharina Fleischhauer
Marta Franceschetti
P304
616-628.e2
P356
10.1016/J.EXPHEM.2009.01.010
P577
2009-05-01T00:00:00Z